To evaluate the prognostic significance of traditional cardiopulmonary exercise testing (CPET) parameters in chronic heart failure (CHF) patients treated with beta-blockers.
Introduction
In 1991, with the publication of the cornerstone manuscript of Mancini et al., 1 it became clear that the prognostic information obtained from cardiopulmonary exercise testing (CPET) could be useful in the management of chronic heart failure (CHF) patients, in particular to optimize timing for heart transplantation. Further studies suggested that peak oxygen consumption (peak VO 2 ) alone, while a powerful prognostic index, could be integrated with other exertional gas exchange variables, 2 -10 and above all the slope of minute ventilation (VE) vs. carbon dioxide production (VE/VCO 2 slope). 11 Today, a reassessment of the significance of CPET traditional prognostic parameters is necessary in CHF patients treated with beta-blockers for three reasons: first, few earlier studies incorporated beta-blocker patients 11 -16 ; secondly, beta-blocker therapy has been homogeneously associated with a substantial reduction in mortality in CHF, 17 with no or marginally impact on peak VO 2 18 and uncertain effects on VE/VCO 2 slope 19, 20 ; finally, only a few studies have evaluated supplementary CPET variables distinctively in addition to peak VO 2 . 13 -16 Thus, the aim of the study was to assess the prognostic effectiveness of traditional CPET risk index in CHF patients regularly treated with beta-blockers.
Methods

Study population
The study cohort consisted of consecutive CHF patients, treated with carvedilol: the present report is a retrospective analysis of data collected prospectively. Eligibility criteria were (i) echocardiographic left ventricular ejection fraction (LVEF) 40%; (ii) ability to perform CPET, stopped for fatigue and/or dyspnoea with a peak respiratory exchange ratio (RER) !1.05, in order to avoid inappropriate prognostic stratification due to poor patient motivation 8 ; (iii) clinical stability defined as no change in NYHA class or absence of hospitalization for heart failure and stable medical treatment during the month before CPET, (iv) a 12 week carvedilol maintenance period before CPET, (v) minimum carvedilol daily dose of 12.5 mgr, and (vi) minimal follow-up of at least 1 year for surviving patients. Patients who initiated carvedilol, or who definitively withdrew treatment, during follow-up and those treated with beta-blockers other than carvedilol were excluded. Patients with primary valve disease, myocardial infarction within the previous 3 months, unstable angina, peripheral vascular disease, chronic lung disease, neuromuscular disease, or with orthopaedic limitation were proscribed.
The study was approved by the institutional Ethics Committee and all patients gave written informed consent.
Cardiopulmonary exercise testing
CPET was performed on a bicycle ergometer with a ramp protocol of 10 W/min and with breath-by-breath respiratory gas exchange measured by a computerized metabolic cart (Sensormedics, Vmax29, Yorba Linda, CA, USA). Details of the test protocol have been published before. 7 Blood pressure was measured manually at rest and every 3 min during incremental exercise and at peak. The electrocardiogram and heart rate (HR) were monitored at rest and throughout exercise at 1 min intervals.
Measured and derived cardiopulmonary exercise testing parameters
To improve the physiological validity of peak oxygen consumption (VO 2 ) in the presence of exertional oscillatory ventilation (EOV), we recorded the mean value of VO 2 during the last 60 s of the test in all patients. Predicted peak VO 2 was determined by using a gender-, age-, height-, and weight-adjusted and protocol-specific formula. 21 The ventilatory anaerobic threshold (VAT) was detected using the V-slope method. 22 Peak oxygen pulse was delineated as peak VO 2 divided by peak HR and was expressed in millilitres per beat, 9 whereas peak circulatory power (CP) was calculated as the product of peak VO 2 (mL/kg/min) and peak systolic blood pressure (SBP, mmHg). 5 Ventilatory response during exercise was measured using four parameters: (i) VE/VCO 2 slope, calculated as a linear regression function from the whole exercise period 3 ; (ii) VE/VCO 2 at peak of exercise, as mean value during the last 60 s of the exercise period 4 ; (iii) the oxygen uptake efficiency slope (OUES), the relationship between VO 2 and VE, via a logarithmic transformation of VE (VO 2 ¼ a log 10 VE þ b; a ¼ OUES) 23 ; and (iv) EOV, visually determined as cyclic fluctuations in minute ventilation lasting .60% of the exercise duration and with an amplitude of .15% of the average amplitude of cyclic fluctuations. Survival analysis considered death due to cardiovascular disease; patients who died of non-cardiac-related causes or underwent heart transplantation were evaluated as 'censored'.
Survival was estimated by the product-limit Kaplan-Meier method; differences between survival curves were evaluated with the log-rank
The prognostic value of variables was determined using univariate and multivariable Cox proportional-hazards regression analysis. 25 First, a Cox model was fitted to each risk factor; the variables that showed a significant association with the outcome (P , 0.01) were included in the multivariable analysis, 25 using backward elimination method.
To address the risk of potential fitting problems, due to the limited number of events relative to the number of independent variables, 26 the following internal verification steps 27, 28 concerning model fit, discrimination, and calibration were carried out.
(1) Model validation was performed via the relative frequency of selection of variables in 200 bootstrap samples obtained from original data sets using random sampling with replacement; the multivariable modelling procedure was repeated in each bootstrap sample, and the percentage of times the covariates significantly added to the model was computed. The variables determined in the starting model should be present at least in 70% of the bootstrapped selection results.
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(2) Evaluation of the discrimination ability of the model was performed using Harrell's C concordance index, the proportion of all usable subject pairs in which the predictions and outcomes are concordant: a value of 0.5 indicates no predictive discrimination and a value of 1.0 indicates perfect separation of patients with different outcomes. First, we estimated the optimism in C index due to overfitting 27 using 200 bootstrap samples, then the optimism value was subtracted from model C index to produce 'honest' C estimates. shrinkage was applied to estimates of the regression coefficients of the model for the total population.
The proportional hazard assumptions of Cox' models were verified by plotting smoothed scaled Schoenfeld residuals with 95% confidence intervals and by searching for the interaction between the covariate and time, and linearity assumption for continuous variables was assessed graphically using martingale residuals.
Systolic blood pressure and prognosis in heart failure All calculations were performed using the STATA w 10 system (StataCorp, College Station, TX, USA).
Results
From July 1995 to January 2005, 903 patients were screened: 271 patients were excluded because of LVEF .40% (n ¼ 25), peak RER ,1.05 (n ¼ 36), exercise limitation for other reasons than fatigue or dyspnoea (n ¼ 54), clinical instability in 1 month period before CPET (n ¼ 24), carvedilol abandonment during follow-up (n ¼ 50), daily carvedilol dose ,12.5 mgr (n ¼ 24), treatment with beta-blockers other than carvedilol (n ¼ 26), and ,1 year follow-up (when all other criteria were fulfilled) (n ¼ 32). One patient was excluded due to high number of missing values; thus, 631 patients were incorporated in this report ( Tables 1 and 2 ). Carvedilol mean daily dose was 20.5 + 11 mg (12.5-75 mg/once a day). No patient was lost during the follow-up which lasted 3.8 + 1.4 years: the scheduled timing of last follow-up assessment was in August 2006. Seventy-nine (13%) patients died of cardiac causes. Mean follow-up for patients with and without events was 2.2 + 1.4 and 4.0 + 1.2 years, respectively. Actuarial 2 and 4 year survival rates were 94 and 88%, respectively.
Mortality was higher in female, in patients treated with lower mean daily dose of carvedilol (both P , 0.05) and in patients with EOV, and those with higher prescription of diuretics and NYHA class, lower LVEF, peak VO 2 , per cent predicted VO 2 , O 2 pulse, peak CP, OUES, peak HR, resting and peak SBP, and a higher peak and VE/VCO 2 slope (all with P , 0.01) ( Tables 1 and  2) : VAT was more frequently detected in patients without cardiac event ( For abbreviations, see Tables 1 -3. elimination, only peak SPB, LVEF, and EOV were selected as independent predictors (Table 4 ) as confirmed by model validation on 200 bootstrap samples; peak SBP, LVEF, and EOV were selected, respectively, with a frequency of 98, 94, and 75%, whereas all the other candidates were ,40%. Discrimination ability of the model obtained, as measured by C concordance index corrected for optimism, was 0.74. Penalization was applied to the estimated regression coefficients using a shrinkage factor of 0.83. Both EOV and peak SBP were selected, again, as the most powerful predictive parameters when multivariable analysis was replicated including only CPET variables (peak VO 2 , per cent predicted VO 2 , O 2 pulse, peak HR, peak SBP, EOV, peak and VE/ VCO 2 slope), confirming that their prognostic authority was not distorted by acknowledged clinical risk factors (LVEF, NYHA, AF, diuretic use, and so on).
Even though associated with higher total mortality rate compared with non-EOV (43 vs. 11%: Figure 1) , EOV was excluded from subsequent analysis since it was detected only in 42 patients (7%). In patients without EOV (non-EOV: 589 patients), univariate Cox proportional hazard regression was replicated on all aforementioned clinical and exertional parameters except EOV: NYHA class, LVEF, peak VO 2 , per cent predicted VO 2 , OUES, peak CP, and peak SBP (all with P , 0.01) were significantly related to cardiovascular death (Table 5) . Again, peak CP and OUES were excluded from the confounder set. At multivariable Cox analysis, the most powerful independent predictors were peak SPB, LVEF, and peak VO 2 ( Table 4) . The model validation procedure selected peak SBP, LVEF, and peak VO 2 , respectively, with a frequency of 97, 94, and 72%, all other candidates ,40%. C concordance index for the model was 0.73.
Discussion
Almost all conventional prognostic 'pre-beta-blocker era' CPET parameters were related to outcome in this large consecutive cohort of CHF patients constantly treated with carvedilol, but only EOV and peak SBP significantly contribute to discriminate prognosis in addition to acknowledged clinical variables. In this population, although EOV considerably enhanced risk stratification, other ventilatory efficiency indexes (VE/VCO 2 slope, peak VE/VCO 2 , and OUES) showed less impressive predictive advice. Peak SPB substantially improved prognosis stratification in the majority of non-EOV patients: every 5 mmHg increase was associated with 11% risk reduction.
Several studies shifted emphasis towards numerous supplementary CPET parameters, in lieu of or in combination with peak VO 2 , in estimating risk in the pre-beta-blocker era, 2 -10 but data are scant and contradictory in beta-blocker cohorts. No supplementary predictive CPET parameter was selected in 236 CHF patients receiving carvedilol 13 and in 909 ones, treated with different betablockers, 14 although both VE/VCO 2 slope and peak CP were prognostically superior to peak VO 2 , irrespective of beta-blocker use, in two recent experiences. 15, 16 That lower peak SBP conveys prognostic information is not a new concept in cardiac patients without 32 or with symptomatic heart failure. 33, 34 The combination of peak SPB and per cent predicted peak VO 2 significantly enhanced risk stratification in 500 CHF patients referred for heart transplantation 33 : peak SPB ,120 mmHg was associated with poor 3 year survival rate in patients with peak VO 2 ,14 mL/kg/min. Again, peak SPB was an independent predictor of all-cause mortality, superior to acknowledged risk factors, such as NYHA class, peak VO 2 , N-BNP levels, and peak CP [calculated from the product of peak VO 2 and mean arterial pressure (MAP)], in 85 mild -moderate CHF patients, with mean peak VO 2 of 21 + 6 mL/kg/min. 34 On the other hand, peak CP, calculated as the product of either peak VO 2 and peak MAP 35 or peak VO 2 and peak SBP, 5 was predictive in two unselected CHF cohorts with moderate exercise intolerance (peak VO 2 20.3 + 5.6 and 23.1 + 9 mL/kg/min), whereas exercise cardiac power (ECP), defined as the product of peak VO 2 (expressed as per cent predicted value) and SBP, 36 was the most powerful predictor of mortality in 154 CHF patients with peak VO 2 of 18.8 + 0.4 mL/kg/min. Overall, present and previous findings 5,32 -36 underline the prognostic importance of SBP, either alone or as integrated measure (CP or ECP), adding verve to the debate about the utility of direct and indirect cardiac function exercise parameters in estimating risk in CHF. The prognostic impact of peak VO 2 is generally thought to be linked with cardiac output; however, direct measurements like peak cardiac power output (CPO), calculated as the product of cardiac output and mean arterial blood pressure, may be even stronger predictor, 37 -39 in virtue of the fact that peak VO 2 is influenced also by non-cardiac factors (age, motivation, muscle deconditioning, anaemia, obesity). Similarly, auxiliary prognostic CPET parameters, such as peak VE/VCO 2 , VE/VCO 2 slope, EOV, OUES peak RER, O 2 pulse, are indirectly related to cardiac output, and therefore can be judged as markers of severity of organ failure, but direct means to improve these values not necessarily indicates an improvement in cardiac function. Certainly, both peak SBP and CP 40 are not perfect surrogates of cardiac output. Physiologically, SBP reflects the performance of the cardiac pump in the context of its function, having the ability to generate both flow (cardiac output) and (blood) pressure but, in the complex interplay of circulatory re-adjustment during exercise, the increase of arterial pressure is the result of multiple stimulatory effects of the mass discharge of the sympathetic nervous system throughout the body, including vasoconstriction of the arterioles in most body tissue beside the active muscles, increasing pumping activity of the heart and increase in mean systemic filling pressure. 41 On the other hand, the assumption that CP mirrors CPO at peak exercise is conceptually true if AVO 2 difference does not significantly differ at peak exercise among patients, but, in practice, at a given cardiac work, variability of AVO 2 would directly cause variation in calculation CP, and, in addition, interpatient variability of AVO 2 , pharmacological interventions, haemoglobin concentration (anaemia), or coexisting lung disease could all lead to an erroneously low estimate of cardiac power. Nevertheless, since low pressure-generating capacity is a hallmark of a very poor heart with a poor outlook, 42 blood pressure performance may have a prominent role. In view of this, Cotter et al. 43 suggested that there could be a hierarchy of precision of exercise measures in CHF, with the most indirect measures, such as NYHA functional class, exercise duration, and 6 min walking distance, at the lower end of the hierarchy; peak VO 2 and supplementary measures such as ventilatory parameters in the middle of the hierarchy;
and the direct measures of cardiac reserve, including CPO, being the most predictive. Even so, drawbacks in measuring either invasively or non-invasively cardiac output 38 are acknowledged, counting limited facilities of equipment, questions on the validity and reliability of true measurement at peak exercise, requirement of considerable experience in exercise physiology to run the program effectively, and, for invasive procedures, safety issues. Both peak SBP and peak CP overcome these difficulties since they are easy to measure, non-invasive parameters, available from any CPET when it is conducted at its maximum, without the need for special equipment.
Limitations
Our low mortality rate may be a sign of the fact that the present cohort consisted in an unselected consecutive CHF population reflecting clinical practice in general cardiology in a tertiary referral centre which is not a cardiac transplant unit: as a standard practice, we tested our patients when their treatment had been optimized and their functional status was as good as could be achieved medically. In view of that, the majority of patients were in NYHA classes I and II. Moreover, owing to the pharmacological dissimilarity among beta-blockers and different prognostic impact of distinctive EOV definitions, present results should cautiously be applied to CHF patients treated with diverse beta-blockers agents or with other EOV outlining. In addition, although the present study includes several hundred patients, EOV was an unusual breathing phenomenon that may be considered a weakness of this report; nonetheless, both follow-up duration and substantial event rate authorize a reasonable interpretation of EOV prognostic significance. Finally, since the study was designed to investigate the predictive power of CPET parameters only, nothing can be said on the prognostic relevance of peak SBP in relation to other acknowledged risk factors, such as HF duration or renal function, sodium, BNP; other studies, with an external validation group and appropriate follow-up, are required to address these issues.
Conclusions
The application of evidence-based therapies can and will continue to change prognostic information. Thus, predicting models need periodic updating to control for evolving standards of care. In CHF patients, regularly treated with beta-blockers, CPET haemodynamic-derived parameters, peak SBP and EOV, are efficient risk predictors, whereas other ventilatory efficiency indexes are less impressive. Also, when EOV is not present, peak SBP enhanced risk evaluation beyond other CPET parameters. Further studies are warranted to authenticate the present remarks.
